EU/3/18/2050

About

On 31 July 2018, orphan designation (EU/3/18/2050) was granted by the European Commission to AstraZeneca AB, Sweden, for selumetinib for the treatment of neurofibromatosis type 1.

Key facts

Active substance
Selumetinib
Disease / condition
Treatment of neurofibromatosis type 1
Date of decision
31/07/2018
Outcome
Positive
Orphan decision number
EU/3/18/2050

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

AstraZeneca AB
SE-151 85 Södertälje
Sweden
Tel. + 46 8 553 260 00
E-mail: orphandrugs@astrazeneca.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating